SCTX

Conviction 0HealthcareScan · Fri, Sep 25, 2026

Scribe Therapeutics, Inc. (SCTX) closed at $21.33 (-1.30%) on Sep 25, 2026. RSI(14) 37, -42.7% from its 52-week high, -1.5% year to date. Sector: Healthcare · Biotechnology.

SCTX$21.33-1.30%

ResistanceSupportVol 14Insider buy

Vol MA14 464.44K

Jul 24Aug 6Aug 19Aug 31Sep 14Sep 25

Scribe Therapeutics, Inc.Biotechnology

Price21.33

Change-1.30%

Gap+2.55%

Rel volume0.77×

Avg volume370.91K

Avg $ vol10.94M

SMA 2028.96

SMA 50—

SMA 200—

Price vs 50—

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 32.86

RSI (14)37

MACD hist-1.26

MACD cross—

Stoch %K / %D7 / 8

ADX (14)21

+DI / −DI15 / 28

RSI divergence—

MACD divergence—

ATR %18.05%

ADR %12.78%

52w high37.25

52w low18.06

From 52w high-42.74%

Above 52w low+18.11%

New 52w highNo

SqueezeFired

Bollinger width40.33%

%B-0.15

Donchian pos7.16%

Donchian high35.40

Donchian low20.25

AVWAP (52w high)30.79

vs AVWAP high-30.73%

AVWAP (52w low)28.41

vs AVWAP low-24.92%

OBV trendUp

Chaikin MF (20)-0.30

Today vs 20d0.77×

Avg vol (14d)451.76K

Avg vol (20d)370.91K

Avg $ vol (20d)10.94M

Market cap403.81M

RS Rating—

RS 3m (vs SPY)—

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank9.1

1 week-35.36%

1 month-32.71%

3 months—

6 months—

1 year—

YTD-1.48%

P/E—

P/B-2.45

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current0.57

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target51.75

Target upside142.62%

Analyst ratingBuy

Institutional—

Ent. value368.23M

Revenue1.92M

Net income-6.48M

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out—

Employees—

Listed—

Free float6.89M

Float %36.4%

Short interest778.19K

Days to cover2.6d

Short volume83.7%

Squeeze score56 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$3.84 vs −$6.20

Last surprise+38.1% beat

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank9.1 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance37.50

Support23.15

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in SCTX

All disclosures →

No recent disclosed trades by Congress in SCTX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in SCTX · open-market 3 buys

Insider	Side	Shares	Value	Traded	Filed
Aghazadeh Behzad Director · Common Stock, par value $0.0001 per share · 2026-07-28	Buy	7.91K	$144K	2026-07-28	2026-07-28
Aghazadeh Behzad Director · Common Stock, par value $0.0001 per share · 2026-07-24	Buy	2.33M	$35M	2026-07-24	2026-07-28
Aghazadeh Behzad Director · Common Stock, par value $0.0001 per share · 2026-07-24	Buy	50K	$1.1M	2026-07-24	2026-07-28
Staahl Brett 10% owner · Stock Option (Right to Buy) · 2026-07-23	Grant	19.39K	—	2026-07-23	2026-07-28
Staahl Brett 10% owner · Performance-based Stock Option (Right to Buy) · 2026-07-23	Grant	19.39K	—	2026-07-23	2026-07-28
Staahl Brett 10% owner · Stock Option (Right to Buy) · 2026-03-13	Grant	4.75K	—	2026-03-13	2026-07-28
Lucas Svetlana Chief Business Officer · Performance-based Stock Option (Right to Buy) · 2026-07-23	Grant	109.43K	—	2026-07-23	2026-07-27
Watson James Dean Director · Stock Option (Right to Buy) · 2026-07-23	Grant	14.72K	—	2026-07-23	2026-07-27
Aghazadeh Behzad Director · Stock Option (Right to Buy) · 2026-07-23	Grant	14.72K	—	2026-07-23	2026-07-27
Bleharski Joshua Director · Stock Option (Right to Buy) · 2026-07-23	Grant	14.72K	—	2026-07-23	2026-07-27

SEC filings

EDGAR filings in SCTX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.